Knight Therapeutics Announces Relaunch of MYFEMBREE in Canada

MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched MYFEMBREE (relugolix/estradiol/norethindrone acetate) in Canada.

In June 2024, Knight and Sumitomo Pharma America Inc. (“SMPA”) announced that Knight and SMPA’s affiliates had entered into exclusive license and supply agreements to commercialize MYFEMBREE (relugolix/estradiol/norethindrone acetate), ORGOVYX (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight acquired certain mature products (the “Mature Products”, together with MYFEMBREE, ORGOVYX and vibegron, the “Products”).

MYFEMBREE is a fixed-dose combination of relugolix, estradiol, and norethindrone acetate and is the first oral prescription treatment for both the management of heavy menstrual bleeding associated with uterine fibroids and the management of moderate to severe pain associated with endometriosis in pre-menopausal women. MYFEMBREE was approved by Health Canada in September of 2023 and was launched in February 2024. Based on IQVIA, the total gonadotropin-releasing hormone receptor (GnRH) agonist and antagonist sales for endometriosis and uterine fibroids in Canada is estimated at $45 million and has been growing at a five-year CAGR of 8%. According to IQVIA Canada, in 2024, the sales of MYFEMBREE were approximately $2.9 million.

“The relaunch of MYFEMBREE provides physicians an effective treatment option for the management of uterine fibroids and endometriosis, conditions that continue to impact so many women,” said Samira Sakhia, President and CEO of Knight. “MYFEMBREE strengthens our women’s health portfolio and benefit from the synergies of our existing commercial and medical infrastructure.”

About MYFEMBREE

MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg tablets) was approved by Health Canada in September 2023 making it the first oral prescription treatment for both the management of heavy menstrual bleeding associated with uterine fibroids and for the management of moderate to severe pain associated with endometriosis in pre-menopausal women.¹

About Uterine Fibroids

Uterine fibroids are the most common benign tumors found in women of reproductive age, occurring in 20–30% of females and 70–80% being detected by age 50.^2,3 They are frequently asymptomatic, although they can cause symptoms such as heavy menstrual bleeding, pelvic pressure or pain, urinary and bowel dysfunction, infertility, and pregnancy complications.⁴ Despite their high prevalence and impact, uterine fibroids remain underdiagnosed and undertreated, particularly in low-resource settings where access to screening and treatment is limited.⁵ A growing body of global epidemiological data highlights this gap, underscoring the urgent need for broader awareness, earlier diagnosis, and more non-invasive treatment options. Addressing this unmet need could drastically improve outcomes for millions of women worldwide.^6,7